We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+1.17%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$1.63B
AUM Growth
-$171M
Cap. Flow
-$213M
Cap. Flow %
-13.08%
Top 10 Hldgs %
50.48%
Holding
102
New
12
Increased
17
Reduced
20
Closed
14

Top Buys

Rank Stock Value
1
BHC icon
Bausch Health
BHC
+$101M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$28.5M
3
NVDQ
Novadaq Technologies Inc.
NVDQ
+$21.2M
4
AEGR
Aegerion Pharmaceuticals
AEGR
+$14.3M
5
PETX
Aratana Therapeutics, Inc.
PETX
+$14M

Top Sells

Rank Stock Value
1
EBS icon
Emergent Biosolutions
EBS
+$33.1M
2
NVRO
NEVRO CORP.
NVRO
+$21.7M
3
CSII
Cardiovascular Systems, Inc.
CSII
+$19M
4
MASI
Masimo
MASI
+$16.3M
5
SPPI
Spectrum Pharmaceuticals Inc
SPPI
+$15.1M

Sector Composition

Rank Sector Weight
1 Healthcare 78.51%
2 Technology 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$176M 10.84%
8,131,310
+1,465,919
+22% +$28.5M
IWM icon
2
PUT
iShares Russell 2000 ETF
IWM
$81.6B
$130M 7.97%
1,150,000
-2,850,000
-71% -$329M
BHC icon
3
Bausch Health
BHC
$1.76B
$91.5M 5.63%
+900,000
New +$101M
NVRO
4
DELISTED
NEVRO CORP.
NVRO
$81.1M 4.99%
1,201,480
-405,605
-25% -$21.7M
XBI icon
5
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.3B
$70.2M 4.32%
1,000,000
– –
HRTX icon
6
Heron Therapeutics
HRTX
$90.9M
$59.6M 3.67%
2,232,001
+370,000
+20% +$9.89M
TVTX icon
7
Travere Therapeutics
TVTX
$5.18B
$57.1M 3.51%
2,959,790
+350,000
+13% +$6.99M
PGNX
8
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$54.9M 3.38%
8,951,169
– –
AVDL
9
DELISTED
Avadel Pharmaceuticals
AVDL
$53.7M 3.3%
4,394,464
– –
NVDQ
10
DELISTED
Novadaq Technologies Inc.
NVDQ
$46.9M 2.89%
3,683,013
+1,774,365
+93% +$21.2M
AEGR
11
DELISTED
Aegerion Pharmaceuticals
AEGR
$35.5M 2.18%
3,510,291
+1,189,925
+51% +$14.3M
LJPC
12
DELISTED
La Jolla Pharmaceutical Company
LJPC
$31.5M 1.94%
1,165,373
+70,000
+6% +$1.91M
ANGO icon
13
AngioDynamics
ANGO
$566M
$30.3M 1.87%
2,498,527
+100,000
+4% +$1.23M
RXDX
14
DELISTED
Ignyta, Inc.
RXDX
$30.2M 1.86%
2,256,546
– –
EBS icon
15
Emergent Biosolutions
EBS
$393M
$26.9M 1.66%
672,922
-948,910
-59% -$33.1M
BDSI
16
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$22.5M 1.38%
4,688,794
-55,266
-1% -$313K
TLGT
17
DELISTED
Teligent, Inc
TLGT
$20.4M 1.25%
228,773
– –
PETX
18
DELISTED
Aratana Therapeutics, Inc.
PETX
$19.1M 1.18%
3,428,865
+2,119,000
+162% +$14M
SCTL
19
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$18.5M 1.14%
2,296,996
– –
GNMX
20
DELISTED
Aevi Genomic Medicine Inc
GNMX
$18.3M 1.13%
3,045,306
+1,500,000
+97% +$10.2M
ATRC icon
21
AtriCure
ATRC
$1.79B
$18M 1.11%
803,519
+400,000
+99% +$8.24M
PTX
22
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$18M 1.11%
609,083
– –
SPNE
23
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
$17.2M 1.06%
1,000,007
– –
ADXS
24
DELISTED
Advaxis Inc
ADXS
$17M 1.05%
112,701
-3,088
-3% -$530K
IOVA icon
25
Iovance Biotherapeutics
IOVA
$2.25B
$16.3M 1%
2,105,519
– –
1
2 3 4 5

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q4 2015 Portfolio in Review

As of Q4 2015, Broadfin Capital held 102 positions worth $1.63B, down 9.5% from $1.8B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Broadfin Capital withdrew a net $213M in Q4 2015, closing 14 positions and reducing 20 holdings. Its most notable exit was Cardiovascular Systems, Inc., an estimated $19M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 63% a quarter earlier, followed by Technology.

Against the trend, Broadfin Capital opened a new position in Bausch Health worth $91.5M.

  • Broadfin Capital's largest Q4 2015 buy was Bausch Health: 900,000 shares worth $91.5M.
  • Broadfin Capital added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2015, an estimated $28.5M increase.
  • Broadfin Capital's biggest Q4 2015 reduction was Emergent Biosolutions, cutting an estimated $33.1M.
  • Broadfin Capital fully exited Cardiovascular Systems, Inc. in Q4 2015, selling an estimated $19M.
  • Broadfin Capital's ten largest holdings make up 50% of its $1.63B portfolio in Q4 2015.
  • Broadfin Capital opened 12 new positions and closed 14 in Q4 2015.
  • Broadfin Capital's portfolio value fell 9.5% quarter-over-quarter to $1.63B.

Based on Broadfin Capital's 13F filing for Q4 2015, filed 16 Feb 2016.